• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

特罗凯治疗复发或转移子宫内膜癌的II期临床实验

[复制链接]
6368 13 seacat 发表于 2014-1-1 16:13:15 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A.
Author information Princess Margaret Hospital, University Health Network, Bras Family Drug Development Program, University of Toronto, Toronto, Ontario, Canada. amit.oza@uhn.on.ca

Abstract
PURPOSE: Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression. Erlotinib is an orally active, selective inhibitor of EGFR tyrosine kinase activity.

PATIENTS AND METHODS: A multinomial design two-stage phase II study was performed to evaluate single-agent activity of erlotinib in women with advanced endometrial cancer with recurrent or metastatic disease who were chemotherapy naïve and had received up to one line of prior hormonal therapy. Erlotinib was administered at daily dose of 150 mg. Archival tumor tissue was analyzed for EGFR expression by immunohistochemistry (IHC) and gene amplification by fluorescent in situ hybridization (FISH). Mutational status of EGFR was determined in responders.

RESULTS: Thirty-two of 34 entered patients are assessable for response. Treatment was well tolerated and severe toxicity infrequent, with the only grade 4 toxicity being an elevation of transaminases (AST). There were four confirmed partial responses (PRs; 12.5%; 95% CI, 3.5% to 29%) lasting 2 to 36 months. Fifteen patients had stable disease (SD), with median duration of 3.7 months (range, 2 to 12 months). EGFR expression was analyzed in thirty patients; 19 were positive, nine were negative, and two were not assessable. Of the 19 patients who were EGFR positive, three had PR (16%), seven SD, and eight progressive disease, and one was not assessable. No mutations were identified in responders. FISH showed no correlation of response with gene amplification.

CONCLUSION: Erlotinib is well tolerated with an overall objective response rate of 12.5%. Molecular analysis did not identify EGFR mutations in responders or correlation of response with gene amplification.

我的评论:这些病人经过化疗和内分泌治疗,仍然有12.5%的客观反应率,疾病控制率超过50%(PR+SD),另外EGFR的状态跟疗效没有明显关系,所以在目前缺乏足够靶向药的现实下,经历多线治疗晚期子宫内膜病人可以试试特罗凯。
真想一觉醒来,我在小学教室对着小学同桌说:“我做了好长一个梦。”

13条精彩回复,最后回复于 2018-4-2 21:18

lslswk  初中一年级 发表于 2014-9-3 22:27:16 | 显示全部楼层 来自: 北京
谢谢楼主的分享!
绿化保护  初中一年级 发表于 2014-9-8 13:31:19 | 显示全部楼层 来自: 重庆
祝seacat版主中秋节快乐,谢谢您对大家无私的帮助。
kratosgc  小学六年级 发表于 2015-1-2 12:26:58 | 显示全部楼层 来自: 江苏南京
已学习,谢谢
siduozi  小学六年级 发表于 2015-3-31 20:17:13 | 显示全部楼层 来自: 江西
新人,刚刚看到斑竹发的这个帖子,很高兴,虽然还没有搞懂一些问题,需要进一步的学习,但是斑竹提供的这个信息,让我心情大好,谢谢斑竹提供,你辛苦了
【枫】_Z2lZ6  禁止发言 发表于 2015-4-3 23:16:04 | 显示全部楼层 来自: 中国
提示: 作者被禁止或删除 内容自动屏蔽
seacat  版主 发表于 2015-4-4 12:47:49 | 显示全部楼层 来自: 广东广州
【枫】_Z2lZ6 发表于 2015-4-3 23:16
用特罗凯?这是没办法中的办法吗?......SCat,请问下你平常是去哪个网站留意这些前沿信息回来的呀?

www.google.com
真想一觉醒来,我在小学教室对着小学同桌说:“我做了好长一个梦。”
【枫】_Z2lZ6  禁止发言 发表于 2015-4-4 21:47:45 | 显示全部楼层 来自: 中国
提示: 作者被禁止或删除 内容自动屏蔽
stonezhezhe  小学六年级 发表于 2017-4-24 14:26:17 | 显示全部楼层 来自: 湖北武汉
你好,我刚刚给你发过消息,就是子宫内膜癌正在使用PD1的病人,我想寻找能够在PD1使用期间联用的靶向,难道可以选择特罗凯吗?
seacat  版主 发表于 2017-4-24 15:45:01 | 显示全部楼层 来自: 广东广州
stonezhezhe 发表于 2017-4-24 14:26
你好,我刚刚给你发过消息,就是子宫内膜癌正在使用PD1的病人,我想寻找能够在PD1使用期间联用的靶向,难道 ...

PD-1不要联和特罗凯,间质性肺炎风险高。
要联就联合贝伐珠单抗。
真想一觉醒来,我在小学教室对着小学同桌说:“我做了好长一个梦。”

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表